Sector ratings Gilead Sciences, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-20 EST			5-day change	1st Jan Change
124.14 ^USD	-0.62%		+1.95%	+1.14%

01-20	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-20	Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $159 From $153, Maintains Buy Rating	MT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
GILEAD SCIENCES, INC.	154B		AAA
ELI LILLY AND COMPANY	932B		A
JOHNSON & JOHNSON	526B		BBB
ABBVIE INC.	378B		AA
ROCHE HOLDING AG	374B		AA
ASTRAZENECA PLC	282B		A
NOVARTIS AG	278B		AAA
NOVO NORDISK A/S	272B		A
MERCK & CO., INC.	272B		A
AMGEN INC.	178B		A
PFIZER INC.	145B		BBB
VERTEX PHARMACEUTICALS INCORPORATED	112B		AA
SANOFI	111B		A
BRISTOL-MYERS SQUIBB COMPANY	110B		A
GSK PLC	96.99B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	85.9B		AA
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	57.77B		AA
TAKEDA PHARMACEUTICAL COMPANY LIMITED	50.63B		AA
BAYER AG	49.47B		AA
Average	226.43B		AA
Weighted average by Cap.			AA